Evidence map›Paper›PMID 42123559›Full record

ArticleInternational journal of molecular sciences2026

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Scott Strum, Clodagh Murray, Sofia Genta, Enrique Sanz-Garcia, Albiruni Razak, Stephanie Lheureux, Christodoulos Pipinikas, Ben X Wang, Amber Chevalier, Christopher G Smith and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Scott StrumDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0003-3618-9936
Clodagh MurrayNeoGenomics, Inc., Fort Myers, FL 33912, USA.
Sofia GentaDepartment of Oncology, Queen's School of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Enrique Sanz-GarciaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Albiruni RazakDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Stephanie LheureuxDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Christodoulos PipinikasNeoGenomics, Inc., Fort Myers, FL 33912, USA.
Ben X WangDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Amber ChevalierNeoGenomics, Inc., Fort Myers, FL 33912, USA.
Christopher G SmithNeoGenomics, Inc., Fort Myers, FL 33912, USA.ORCID 0000-0001-7357-2737
Anna SpreaficoDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-3034-3042
Lillian L SiuDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-3500-0540
Mitchell ElliottDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0001-6711-7287
David W CesconDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-1080-0998

Funding

BMO Financial Chair in Precision Genomics BMO Financial Chair in Precision Genomics
6 · The paper itself

Abstract

Circulating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed ctDNA assay. Participant samples were collected at the University Health Network across six study cohorts. A total of 273 patients with stage II-IV cancers spanning 16 tumor types were analyzed using a personalized tumor-informed assay (RaDaR

Indexed as

Biomarkers, TumorCirculating Tumor DNANeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingBiomarkers, TumorCirculating Tumor DNAbiomarkerscancerctDNAMRD

Identifiers

PMID42123559
PMCPMC13164046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.